Patents by Inventor Erik Verner

Erik Verner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100022561
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 7, 2009
    Publication date: January 28, 2010
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20100004270
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 7, 2009
    Publication date: January 7, 2010
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTONS TYROSINE KINASE
    Publication number: 20090181987
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 20, 2009
    Publication date: July 16, 2009
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 7514444
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: April 7, 2009
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • BRUTON'S TYROSINE KINASE ACTIVITY PROBE AND METHOD OF USING
    Publication number: 20080214501
    Abstract: Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.
    Type: Application
    Filed: November 5, 2007
    Publication date: September 4, 2008
    Applicant: PHARMACYCLICS, INC.
    Inventors: Zhengying PAN, Shyr Jiann Li, Heleen SCHEERENS, Lee HONIGBERG, Erik VERNER
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20080139582
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: December 26, 2007
    Publication date: June 12, 2008
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee HONIGBERG, Erik VERNER, Zhengying PAN
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20080108636
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: December 28, 2006
    Publication date: May 8, 2008
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20080076921
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: March 28, 2007
    Publication date: March 27, 2008
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
    Publication number: 20080004331
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: August 6, 2007
    Publication date: January 3, 2008
    Applicant: Pharmacyclics, Inc.
    Inventors: Erik Verner, Martin Sendzik, Chitra Baskaran, Joseph Buggy, James Robinson
  • NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
    Publication number: 20070293540
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: July 30, 2007
    Publication date: December 20, 2007
    Inventors: Erik Verner, Martin Sendzik, Chitra Baskaran, Joseph Buggy, James Robinson
  • INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20070281934
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: March 16, 2007
    Publication date: December 6, 2007
    Applicant: PHARMACYCLICS, INC.
    Inventors: Joseph Buggy, Sriram Balasubramanian, Erik Verner, Vincent Tai, Chang-Sun Lee
  • Mesylate salt of 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide
    Publication number: 20070105939
    Abstract: The present invention is directed to the mesylate salt of 5-(2-dimethylamino-ethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide, pharmaceutical compositions and processes for preparing the same.
    Type: Application
    Filed: May 24, 2006
    Publication date: May 10, 2007
    Applicant: Pharmacyclics, Inc.
    Inventor: Erik Verner
  • Novel bicyclic hydroxamates as inhibitors of histone deacetylase
    Publication number: 20060058553
    Abstract: The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity.
    Type: Application
    Filed: February 7, 2003
    Publication date: March 16, 2006
    Applicant: AXYS PHARMACEUTICALS, INC.
    Inventors: Ellen Leahy, Erik Verner
  • Novel hydroxamates as therapeutic agents
    Publication number: 20050187261
    Abstract: The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.
    Type: Application
    Filed: April 6, 2004
    Publication date: August 25, 2005
    Applicant: AXYS PHARMACEUTICALS, INC.
    Inventors: Erik Verner, Martin Sendzik, Chitra Baskaran, Joseph Buggy, James Robinson